Radiopharm Theranostics Limited (RAD.AX)
| Previous close | 0.1200 |
| Open | 0.1250 |
| Bid | 0.1050 x N/A |
| Ask | 0.1250 x N/A |
| Day's range | 0.1200 - 0.1250 |
| 52-week range | 0.0850 - 0.2150 |
| Volume | |
| Avg. volume | 235,786 |
| Market cap | 40.718M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.57 |
Simply Wall St.Radiopharm Theranostics Full Year 2023 Earnings: AU$0.11 loss per share (vs AU$0.17 loss in FY 2022)
Radiopharm Theranostics ( ASX:RAD ) Full Year 2023 Results Key Financial Results Net loss: AU$34.6m (loss widened by...
GlobeNewswireRadiopharm Theranostics Expands Supply Agreement With TerThera for Terbium-161 Isotope Use in Prostate Cancer
Agreement will supply Tb-161 for RAD 402, a potential next generation radiopharmaceutical for treatment of advanced prostate cancerSYDNEY, Australia, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce an expanded agreement with TerThera to supply the Company with Terbium-161 (Tb-161). The Tb-161 isotope will be linked to a proprietary monoc
- GlobeNewswire
Diamond Equity Research to Host Global Select Emerging Growth Invitational Virtual Investor Conference on June 13th, 2023
Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional InvestorsNEW YORK, June 09, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its Global Select Spotlight Emerging Growth Invitational Investor Conference on June 13, 2023. The conference, which is open to all retail and institutional investors, will consist of a series of tw
